XML 28 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' Deficit
6 Months Ended
Jun. 30, 2021
Shareholders' Deficit  
Shareholders' Deficit

Note 10—Shareholders’ Deficit

Common Stock and Warrants

On March 1, 2021, we entered into a sales agreement to sell shares of our common stock having an aggregate offering price of up to $150.0 million, from time to time, through an “at the market” equity offering program. As of June 30, 2021, we have not sold any shares under this program.

In March 2021, a cashless exercise was executed for 43,115 warrants, resulting in the issuance of 24,901 shares of our common stock. As of June 30, 2021, 200,000 warrants remained outstanding with an exercise price of $23.00 per share. The warrants expire on April 12, 2023.

Amendment of 2017 Omnibus Incentive Compensation Plan (the “Plan”)

At the June 11, 2021 annual meeting, shareholders approved the increase of the number of shares of common stock authorized for issuance under the Plan by 4,000,000, to bring the total number of shares of common stock authorized to 12,600,000.

Interim Condensed Consolidated Statements of Shareholders’ Deficit

The changes in interim balances of the components of our shareholders’ deficit are as follows:

Additional

Common

Paid-In

Accumulated

    

Stock

    

Capital

    

Deficit

Total

(In thousands)

Balance January 1, 2021

$

616

$

751,304

$

(872,672)

$

(120,752)

Exercise of stock options and warrants

6

6,327

6,333

At the market offering costs

(241)

(241)

Cumulative effect of adopting ASU 2020-06

(70,779)

(4,697)

(75,476)

Stock-based compensation expense

3,271

3,271

Net loss

(35,090)

(35,090)

Balance March 31, 2021

622

689,882

(912,459)

(221,955)

Exercise of stock options

2

1,133

1,135

Stock-based compensation expense

3,117

3,117

Net loss

(28,593)

(28,593)

Balance June 30, 2021

$

624

$

694,132

$

(941,052)

$

(246,296)

Additional

Common

Paid-In

Accumulated

    

Stock

    

Capital

    

Deficit

Total

(In thousands)

Balance January 1, 2020

$

542

$

625,048

$

(734,611)

$

(109,021)

Exercise of stock options

3

2,709

2,712

Stock-based compensation expense

3,476

3,476

Net loss

(29,031)

(29,031)

Balance March 31, 2020

545

631,233

(763,642)

(131,864)

Exercise of stock options

66

66

Stock-based compensation expense

3,822

3,822

Net loss

(33,294)

(33,294)

Balance June 30, 2020

$

545

$

635,121

$

(796,936)

$

(161,270)